New drug cocktail targets Hard-to-Treat lung cancer
NCT ID NCT07377916
First seen Feb 01, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This study tests a combination of two drugs, SHR-A1811 and pertuzumab, in people with advanced non-small cell lung cancer that has HER2 mutations or overexpression and has worsened after at least one prior treatment. The goal is to see if this combo can shrink tumors or slow disease progression. About 60 participants will receive the treatment intravenously every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-A1811 (a drug) combined with pertuzumab
What this could lead to
If successful, this combination could offer a new treatment option to control advanced HER2-altered lung cancer after initial therapy fails.
What could go wrong
This is an early exploratory study with only 60 participants and no control group. The treatment may not improve outcomes and could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.